A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid Tumors

Phase 1 Not yet recruiting 18 enrolled Zhejiang University

NaSingle-groupOpen-labelTreatment

Summary

This is a single-center, single-arm ，open-label ，dose escalation and dose extension study. In this study we plan to evaluate the safety and efficacy of CD70-targeting UCAR-T cells in the treatment of CD70-positive refractory or relapsed solid tumors, and obtain recommended doses and infusion patterns.

Timeline

Start: 2024-04-22
Primary completion: 2027-04-21
Completion: 2029-04-21

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CHT101	Cell therapy	3e+06 cells/kg	Intravenous
Subject	CHT101	Cell therapy	6e+06 cells/kg	Intravenous
Subject	CHT101	Cell therapy	8e+06 cells/kg	Intravenous
Subject	CHT101	Cell therapy	1e+07 cells/kg	Intravenous

A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid Tumors

Summary

Timeline

Drugs

Indications